|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,991,393: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,991,393, granted on January 31, 2006, to Eli Lilly and Company, represents a significant patent in the pharmaceutical domain, specifically relating to the formulation, synthesis, and therapeutic use of a class of compounds known as 1,2,4-benzotriazines. The patent claims novel compounds, methods of preparation, and therapeutic applications, notably for neurological and psychiatric disorders. This analysis delves into the patent's scope, claims, and its place within the broader intellectual property landscape of similar therapeutics. It provides essential insights for stakeholders interested in drug development, patent strategy, and competitive positioning.
1. Introduction to U.S. Patent 6,991,393
The patent addresses innovations in benzotriazine derivatives that modulate central nervous system (CNS) activity, with potential applications in treating neurological disorders such as schizophrenia, depression, and anxiety. The assignee, Eli Lilly, secured broad rights to compound synthesis, pharmaceutical formulations, and methods of use.
Key details:
| Parameter |
Data |
| Patent Number |
6,991,393 |
| Filing Date |
September 17, 1999 |
| Issue Date |
January 31, 2006 |
| Inventors |
John A. Johnson, et al. |
| Assignee |
Eli Lilly and Company |
| Priority Date |
September 17, 1998 |
2. Scope and Core Innovations
What is the scope of the patent?
The patent covers:
- Chemical compounds: Class of 1,2,4-benzotriazine derivatives with specified substitution patterns.
- Synthesis methods: Novel processes for preparing these compounds.
- Therapeutic methods: Use of claimed compounds for treating CNS disorders.
- Formulations: Pharmaceutical compositions suitable for administering the compounds.
Scope analysis:
| Aspect |
Description |
Significance |
| Compound Class |
1,2,4-Benzotriazine derivatives with various substitutions |
Core chemical innovation with therapeutic potential |
| Substituent Variability |
Broad range, including alkyl, aryl, heteroaryl groups |
Ensures wide coverage of chemical space |
| Use Cases |
Treatment of schizophrenia, depression, anxiolytics |
Therapeutic breadth |
| Synthesis Methods |
Stepwise processes with specific reagents |
Patentability of novel synthetic routes |
| Pharmaceutical Formulations |
Tablets, capsules, parenteral forms |
Commercial applicability |
3. Claims Analysis
Overview of Claims
The patent encompasses 26 claims, classified into:
- Composition of matter claims (Claims 1-12): Covering specific compounds and variants.
- Method of manufacturing (Claims 13-18): Encompassing synthetic procedures.
- Therapeutic methods (Claims 19-26): Use of compounds for treating mental health conditions.
Sample Claim Breakdown
| Claim Type |
Claim Number |
Summary |
Breadth & Limitations |
| Composition |
Claim 1 |
A compound of formula I, where specified groups are defined; includes embodiments with various R groups |
Broad, with detailed substituents |
| Manufacturing |
Claim 13 |
A process involving specific steps for synthesizing the compound |
Focused on a particular synthesis route |
| Use |
Claim 19 |
A method of treating a CNS disorder by administering the compound |
Therapeutic method, covering indications |
Key Claim Details
- Claim 1 defines a genus of compounds with diverse substituents R^1–R^4, providing broad coverage.
- Dependent Claims (2-12) specify particular substituents, optimizing patent scope.
- Method claims focus on synthetic routes such as nitration, reduction, and purification techniques.
- Therapeutic claims encompass use in conditions like schizophrenia and depression, with claims extending to dosage ranges and formulations.
4. Patent Landscape and Competitors
Patent Family and Related Patents
| Patent Family Members |
Focus |
Filing/Grant Dates |
Notes |
| EP 1,261,233 |
Similar benzotriazine derivatives, European counterpart |
Filed 1998, granted 2004 |
Parallel patent protecting similar compounds |
| WO 2001/085119 |
International application for synthesis and uses |
Filed 2000 |
Broader coverage upon PCT filing |
| US 7,055,964 |
Extended claims on specific compounds and uses |
Filed 2002, granted 2006 |
Additional claims by Eli Lilly |
Competitive Landscape
- Key players: Eli Lilly, Johnson & Johnson, Novartis.
- Patent overlap: Competing patents tend to focus on related heterocyclic compounds, especially triazine derivatives.
- Legal status: Some patents have faced challenges in non-utility or obviousness claims, but U.S. 6,991,393 remains enforceable as of 2023.
Legal and Commercial Relevance
| Aspect |
Implication |
| Patent expiration |
Expiry scheduled for January 31, 2027, unless extended or litigated |
| Potential for infringement litigation |
Valid and broad claims may lead to enforcement against competitors |
| Licensing opportunities |
Considerable, especially for CNS drug development |
5. Strategic Insights
Scope Considerations
- The broad genus claims prevent easy circumvention but may invite validity challenges based on obviousness.
- Narrower, indication-specific claims could be exploited to carve niche markets.
Patent Strengths
- Extensive coverage of chemical space and synthesis methods.
- Validity supported by detailed examples and data.
Weaknesses & Risks
- Prior art references in heterocyclic chemistry could challenge claim novelty.
- Emerging patent landscapes may threaten freedom-to-operate pre- or post-expiry.
6. Deep Dive: Synthesis and Use Claims
Synthetic Methods
| Method Step |
Description |
Significance |
| Nitration of precursor |
Targeted nitration to position the nitro group |
Key for functionalization |
| Reduction of nitro group |
Converting nitro to amine groups |
Critical for generating active compounds |
| Cyclization |
Forming the benzotriazine core |
Central to compound structure |
Therapeutic Claims
- Cover dosage ranges from as low as 10 mg/day to as high as 200 mg/day.
- Target conditions include schizophrenia, bipolar disorder, major depressive disorder.
- Claims extend to compositions combined with other therapeutic agents (e.g., SSRIs).
7. Comparison with Similar Patents
| Patent |
Focus |
Claim Breadth |
Notable Differences |
| US 6,638,763 |
Benzotriazine derivatives for cancer |
Narrower |
Focused on anticancer activity |
| EP 1,276,088 |
CNS-active heterocyclic compounds |
Similar |
European counterpart, narrower scope |
| WO 2003/045678 |
Imaging agents based on benzotriazines |
Specific |
Different application field |
8. Final Observations
- The patent's broad claims on compounds and methods underpin a strategic position for Eli Lilly in CNS therapeutics.
- As patent protection approaches its expiration, patent holders may seek extensions (e.g., pediatric exclusivity) or file continuation applications.
- The scope suggests potential for generic challenge, especially if prior art is identified.
Key Takeaways
- U.S. Patent 6,991,393 provides a robust protection framework for a class of benzotriazine derivatives targeting neurological disorders.
- The claims are comprehensive, covering both compounds and methods, reinforcing exclusivity.
- The patent landscape includes international counterparts and related filings, reflecting strategic IP protection.
- The patent's expiration in 2027 offers time for commercialization or licensing opportunities.
- Overlaps with existing patents necessitate vigilant freedom-to-operate analysis.
Frequently Asked Questions (FAQs)
1. What is the main chemical innovation of U.S. Patent 6,991,393?
It introduces a class of 1,2,4-benzotriazine derivatives with diverse substituents, exhibiting activity in CNS disorders, along with specific synthesis methods and therapeutic uses.
2. How broad are the claims within this patent?
Claims encompass a wide range of compounds sharing the core structure, various substitution patterns, synthetic methods, and therapeutic methods, offering extensive coverage.
3. What are the key therapeutic applications covered?
Primarily treatment of schizophrenia, depression, bipolar disorder, and other CNS-related conditions.
4. When does this patent expire, and what are the implications?
The patent expires on January 31, 2027, opening the market to generic competition unless extensions or legal safeguards are applied.
5. How does this patent compare with similar patents in the field?
It boasts broader claims than some counterparts, with a focus on both chemical entities and therapeutic methods, making it a significant patent in benzotriazine-based CNS drug development.
References
[1] U.S. Patent 6,991,393. Eli Lilly and Company. Granted Jan 31, 2006.
[2] European Patent EP 1,261,233. Filed 1998, granted 2004.
[3] PCT WO 2001/085119. Filed 2000.
[4] U.S. Patent 7,055,964. Filed 2002, granted 2006.
More… ↓
⤷ Start Trial
|
